SecBot SecBot

TVGN

Tevogen Inc.
Nasdaq· Biological Products, (No Diagnostic Substances)· Inc. DE· CIK 0001860871 Biotech & Drug Discovery
$6.28 +0.03 (+0.48%)
Oct 27 4:00 PM ET · prev $6.25
Market cap
$102.8M
Micro cap
Next earnings
Nov 12
in 16 days
1 year
−79.2%
from $30.25 · Oct 28
30 days
−7.1%
from $6.76
52-week range
$3.89–31.40
−80% from high · low Jul 20
Avg volume 20D
7.9K
Oct 23 spike 39.4K
Short interest
55.4K
≈0.3% of shares · −0.3%
Days to cover
10.4
at average volume
Insider net
−$6.6K
0 buyers · 1 seller · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
7
analyzed by SecBot
SecBot read MIXED 4 reports · 90 days
Balance 0 bearish · 0 bullish · 4 neutral oldest → newest, height = score
Avg score ·High conf. 4/4 ·Next Earnings date, Nov 12, 2026
Strongest NEUTRAL Tevogen Inc. received written notice from Nasdaq on September 29, 2026, confirming it regained compliance…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBEARISH

    1 insider sold $6.6K.

  • InstitutionsBEARISH

    Q2 2026: 2 added (0 new), 6 trimmed or exited.

  • Short sellersSTEADY

    Short interest −0.3% to 55.4K shares. 10.4 days to cover, ≈0.3% of shares.

  • TrendDOWNTREND

    10% below its 50-day average.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
VANGUARD CAPITAL MANAGEMENT LLCTRIM23,976$135.7K
UBS Group AGTRIM1,083$6.1K
VANGUARD FIDUCIARY TRUST COTRIM838$4.7K
ROYAL BANK OF CANADAADD154$1.0K
BNP PARIBAS FINANCIAL MARKETSTRIM121$685.00
CITIGROUP INCADD61$345.00
BARCLAYS PLCNEAR_EXIT33$187.00
WELLS FARGO & COMPANY/MNNEAR_EXIT14$79.00

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

last action Mar 2026
Recent actions
DateFirmActionRating
Mar 4, 2026D. Boral Capital
DOWNGRADE
DOWNGRADEHold
Mar 3, 2026D. Boral Capital
MAINTAIN
MAINTAINBuy
Nov 20, 2025D. Boral Capital
MAINTAIN
MAINTAINBuy
Sep 4, 2025D. Boral Capital
MAINTAIN
MAINTAINBuy
Aug 18, 2025D. Boral Capital
MAINTAIN
MAINTAINBuy
Aug 6, 2025D. Boral Capital
MAINTAIN
MAINTAINBuy

Insider ledger

Form 4
$0
bought · 0 insiders
$6.6K
sold · 1 insider
DateInsiderTypeValue
Sep 14, 2026
Desai Kirti
Chief Financial Officer
AWARD750,000 sh
Sep 14, 2026
Saadi Ryan H.
Chief Executive Officer
AWARD8,000,000 sh
Sep 11, 2026
Goh Keow Lin
Director
AWARD75,000 sh
Sep 11, 2026
Patton Curtis L.
Director
AWARD75,000 sh
Sep 11, 2026
PODLOGAR SUSAN M
Director
AWARD75,000 sh
Sep 11, 2026
Sordillo Victor J.
Director
AWARD75,000 sh
Sep 11, 2026
Feike Jeffrey L.
Director
AWARD75,000 sh
Jul 10, 2026
Feike Jeffrey L.
Director
AWARD40,000 sh

Earnings setup

Estimates
Nov 12
reports in 16 days
PeriodEPS est.Range30D rev.Revenue
Current Q———$0.00
Next Q———$0.00
Current FY———$0.00
Next FY———$0.00

Short side

FINRA· Oct 15, 2026
55,420
shares short
-0.3%
vs prior settlement
10.4
days to cover
≈0.3%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 30, 2026 SEC
Tevogen Inc. received written notice from Nasdaq on September 29, 2026, confirming it regained compliance with the $50…
8-K — Impact 4/10
Sep 30, 2026 Other
Tevogen Regains Compliance with Nasdaq Global Market Continued Listing Requirements
Both previously disclosed Nasdaq compliance matters are now closed Both previously disclosed Nasdaq
Sep 16, 2026 SEC
Ryan H. Saadi filed Amendment No. 4 to his Schedule 13D, disclosing receipt of 8,000,000 restricted shares of Tevogen…
SC 13D/A — Impact 4/10
Sep 16, 2026 SEC
Kirti Desai filed an amended Schedule 13D disclosing a grant of 750,000 restricted shares on September 14, 2026…
SC 13D/A — Impact 3/10
Sep 14, 2026 Insider
Desai Kirti was granted 750,000 shares
Chief Financial Officer
Sep 14, 2026 Insider
Saadi Ryan H. was granted 8,000,000 shares
Chief Executive Officer
Sep 11, 2026 Insider
Goh Keow Lin was granted 75,000 shares
Director
Jun 30, 2026 Inst.
VANGUARD CAPITAL MANAGEMENT LLC — TRIM
23,976 shares ($135.7K)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 12, 2026
Earnings date
TVGN Q3 2026 Earnings Scheduled — 2026-11-12
Recent
Sep 30, 2026
Press release
Tevogen Regains Compliance with Nasdaq Global Market Continued Listing Requirements
Both previously disclosed Nasdaq compliance matters are now closed Both previously disclosed Nasdaq compliance matters are now closed
Sep 28, 2026
Listing
Listing Status: TVGN — Normal (was Deficient)
Tevogen Inc. - Common Stock | Nasdaq Financial Status Indicator D → N
Aug 12, 2026
Earnings date
TVGN Q2 2026 Earnings Scheduled — 2026-08-12
Jul 13, 2026
Company news
Tevogen Bio Announces 2026 Annual Meeting of Stockholders
WARREN, N.J., July 13, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN ) announced that its 2026 Annual…
Jun 9, 2026
Earnings
Tevogen Announces Formation of a Healthcare Services Initiative
Tevogen launches Healthcare Services initiative to evaluate MSO and CRO acquisitions with potential to support approximately $100M in annual revenue.

SecBot reports

7 filings · 5 press releases · 0 bullish · 2 bearish · 5 neutral
All TVGN filing & press-release reports (12)